0000874015-16-000145.txt : 20161114 0000874015-16-000145.hdr.sgml : 20161111 20161114185234 ACCESSION NUMBER: 0000874015-16-000145 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161109 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HOUGEN ELIZABETH L CENTRAL INDEX KEY: 0001074773 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 161997275 MAIL ADDRESS: STREET 1: 10070 BARNES CANYON ROAD STREET 2: C/O MOLECULAR BIOSYSTEMS INC CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-11-09 0000874015 IONIS PHARMACEUTICALS INC IONS 0001074773 HOUGEN ELIZABETH L C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP, Finance & CFO Common Stock 2016-11-09 2016-11-09 4 M 0 2500 11.27 A 9048 D Common Stock 2016-11-09 2016-11-09 4 S 0 2500 38.49 D 6548 D Common Stock 2016-11-11 2016-11-11 4 M 0 2500 11.27 A 9048 D Common Stock 2016-11-11 2016-11-11 4 S 0 2500 41.00 D 6548 D Employee Stock Option (right to buy) 11.27 2016-11-09 2016-11-09 4 M 0 2500 0 D 2014-01-04 2017-01-03 Common Stock 2500 7500 D Employee Stock Option (right to buy) 11.27 2016-11-11 2016-11-11 4 M 0 2500 0 D 2014-01-04 2017-01-03 Common Stock 2500 5000 D Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.56, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. /s/B. Lynne Parshall, attorney-in-fact 2016-11-11